Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8258 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
filingDate |
2013-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e38bdefd89cb88662c618f6445a7e66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e65f50862c48d4aaec00394220ac78a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96730552229867423c5c53a88dc312a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d279153ea617123f26ba641a95f8ac4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af226973a2cded1df8049b2cdb9fa5d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76610e1e1fe88d4ce4b3854f46731edd |
publicationDate |
2013-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2013295612-A1 |
titleOfInvention |
Anti-glypican-3 antibody having improved kinetics in plasma |
abstract |
A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11001643-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9975966-B2 |
priorityDate |
2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |